AbbVie Inc.
Develops and sells pharmaceutical medicines, therapies, and cosmetic injectables, spanning oncology, immunology, eye care, neurology, and aesthetics globally.
As of Oct 16, 2026
Summary
AbbVie is a diversified healthcare company trading on the NYSE with a market capitalisation of $501 billion. The stock is showing a bullish technical lean at $285.42, with a one-month return of +8.8% and a one-year return of +29.9%, reflecting sustained upward momentum over the past year.
Price history
As of Oct 16, 2026
Performance
+0.71%
+3.87%
+8.77%
+13.34%
+28.65%
+29.95%
As of Oct 16, 2026
Technical indicators
- 72.3Bearish
- 1.85Bullish
- 50: 260.92 · 200: 230.77Bullish
- $256.30 / $291.40
Technical Bias
Bullish lean
The technical setup for AbbVie Inc. shows a bullish lean overall, with the moving average structure (50-day at 260.92 above the 200-day at 230.77) and MACD momentum reading of 1.85 signalling upside bias, though RSI at 72.3 suggests overbought conditions. This is a derived technical read, not a recommendation, and sits between support at 256.30 and resistance at 291.40 with price currently at 285.42.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 16, 2026
Fundamentals
- $501B
- 77.45
- $3.66
- 9.80%
- +10.2%
- $17.8B
- 0.23
- $188.25 – $291.40
- 2.52%
- Oct 15, 2026
- Oct 30, 2026 (12 days)
As of Oct 18, 2026
Upcoming catalysts
- Earnings report
As of Oct 18, 2026
Latest news
As of Oct 18, 2026
MonkeyTrade's Take on AbbVie Inc.
Short-term outlook
The short-term setup leans bullish, with price well above both the 50-day ($260.92) and 200-day ($230.77) averages and MACD confirming the uptrend after an 8.8% one-month run. That said, RSI at 72.3 signals overbought conditions, so a pullback toward the $256.30 support wouldn't be surprising before any fresh push toward $291.40 resistance. No earnings catalyst is imminent, with the next report not due until October 30, 2026.
Medium-term outlook
AbbVie's 10.2% revenue growth and a 2.5% dividend yield point to a business still expanding and rewarding shareholders while it does so, and the bullish technical lean backs that up over the coming quarters. The sticking point is the 77.45 P/E against a 9.8% profit margin, a gap that leaves little room for disappointment. A margin improvement that brings profitability closer in line with that valuation would be the key development to watch.
Key risks
- The stock's price-to-earnings ratio of 77.45 is well above typical market levels, suggesting investors have priced in a lot of future growth, which raises the risk of disappointment if results fall short.
- AbbVie's profit margin of 9.8% looks thin relative to that lofty valuation, so any pressure on costs or pricing could weigh more heavily on earnings.
- The company's pipeline progress, such as the Phase 3 AFFIRM data for SKYRIZI in Crohn's disease, still needs to translate into commercial results, and clinical or regulatory setbacks remain a possibility.
- Shares are trading close to their 52-week high of $291.40 after a wide 52-week range from $188.25, which can leave less room for error if sentiment shifts.
About AbbVie Inc.
AbbVie Inc. (NYSE: ABBV) is a major player in the Healthcare sector, operating within the Drug Manufacturers - General industry. With a market capitalisation of $501B, it stands as one of the larger names in pharmaceuticals, reflecting its broad footprint in drug development and manufacturing. Its scale means AbbVie's performance is often viewed as a bellwether for trends across the wider drugmaking space, making it a stock many investors keep on their radar when assessing the sector's health.
Looking at AbbVie's key figures offers a window into how the market currently views the business. A price-to-earnings ratio of 77.45 points to a valuation that prices in significant expectations for future earnings. Meanwhile, a dividend yield of +2.5% shows the company returns a portion of its profits to shareholders, a detail income-focused investors often weigh alongside growth considerations when researching the stock.
How to trade AbbVie Inc.
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.